TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Peijia Medical Ltd. ( (HK:9996) ).
Peijia Medical Limited announced the successful first implantation in the first-in-man clinical trial of the Sutra Hemi-valve Transcatheter Mitral Valve Repair System, a key product of Sutra Medical, Inc. The procedure, performed on a high-risk patient with severe mitral regurgitation at Waikato Hospital in New Zealand, marks a significant milestone in the development of innovative cardiac treatments. This advancement highlights Peijia Medical’s strategic investment in cutting-edge medical technologies, potentially enhancing its market position and offering new solutions for patients with limited treatment options.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Limited is a company incorporated in the Cayman Islands, focusing on the medical industry. It holds a strategic investment in Sutra Medical, Inc., a U.S.-based medical device company that designs and develops transcatheter solutions for valvular heart diseases. Peijia Medical is the second largest shareholder of Sutra.
Average Trading Volume: 2,407,370
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.04B
See more insights into 9996 stock on TipRanks’ Stock Analysis page.